AI assistant
Evotec SE — Regulatory Filings 2015
Sep 9, 2015
151_rns_2015-09-09_d2211d24-fba9-4b3d-b408-f6854b8b3949.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 9 September 2015 07:30
Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis
DGAP-News: Evotec AG / Key word(s): Alliance
2015-09-09 / 07:30
Hamburg, Germany - 09 September 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that it has signed an
agreement on a four-year research collaboration with Pfizer Inc. in the
field of tissue fibrosis.
Under the terms of this licence and collaboration agreement, scientists at
Evotec and Pfizer will explore potential novel mechanisms as targeted
anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug
discovery platform whereas Pfizer will provide key technologies and
industrial scope as well as pharmaceutical development and marketing
expertise.
Financial terms of the collaboration include an upfront payment and
potential milestone payments from Pfizer based on the achievement of
specific development and sales milestones.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are
proud about Pfizer partnering with us in our growing initiative in the
fibrosis field utilising one of our internal programmes."
Dr Charles MacKay, Chief Scientific Officer, Inflammation and Immunology at
Pfizer, added: "We believe that Evotec's discovery platform is
well-positioned to deliver potentially innovative approaches to several
areas of tissue fibrosis. We are excited about the possibilities of this
agreement."
Please click on the following link to watch a short video about this new
collaboration:
https://www.youtube.com/channel/UCySUJ6WWgZ9aC0vcO0cs0EA
ABOUT TISSUE FIBROSIS
Fibrosis is a non-physiological wound healing process that can occur in
multiple tissues in response to injury, including physical, chemical and
immunological insults. The progressive accumulation of extracellular matrix
proteins during the scarring process impairs organ recovery and leads to
organ function failure. It is believed that approximately 40% of all
natural deaths in the developed world can be attributed to chronic
fibro-proliferative diseases1), in particular those of the liver, kidney,
heart and lung. With the exception of pirfenidone and nintedanib, which
were recently approved for treatment of idiopathic pulmonary fibrosis,
there are no other effective therapies for the treatment of fibrosis. Thus,
there remains a huge unmet medical need for patients with progressive organ
function decline due to fibrosis.
1) Mehal, Wajahat Z, et al. Expressway to the core of fibrosis. In: Nature
Medicine, Vol. 17, No. 5. Nature America, Inc.; 2011.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
2015-09-09 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News Service
393337 2015-09-09